In summary, our findings demonstrate that IL‐36α expression is associated with poor prognosis in patients with NSCLC, and IL‐36α exerts potent anticancer efficiency in NSCLC involved with, or partly, reducing tumor angiogenesis via inhibiting VEGFA expression. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.